Blog

January 26, 2015April 24, 2018

FYidoctors Announce Major Purchase of Zeiss Cirrus HD-OCTs

With a view toward improving coast to coast coverage with OCT technology, FYidoctors announced a substantial purchase from Carl Zeiss Canada’s Medical Division.

Dr. Alan Ulsifer, CEO and President of FYidoctors indicates, “the purchase is …a big part of our brand”.

In the statement, Moosah Gulam, Vice President at Carl Zeiss Canada, welcomed the choice of FYidoctors.

The OCT purchase builds upon previously announced collaborations between ZEISS and FYidoctors. Last November FYi became the first external laboratory in Canada authorized to manufacture Zeiss lenses. FYidoctors also uses i.Terminal 2.

www.fyidoctors.com

January 23, 2015April 24, 2018

Ted Baker Launches Retro Styles

Fresh for February, new optical styles for men and women from its quintessentially British Ted Baker line blend retro styling with current trends. Wood, unique “T” branding, custom prints inspired by Ted’s apparel collection, and stone set hardware let Ted’s quirky and edgy personality shine through. http://www.tura.com

January 23, 2015April 24, 2018

Photochromic lenses still seen as luxury by consumers

Research and Markets predicts the photochromic lenses market should grow at a compound annual growth rate (CAGR) of 7.6% over the period 2014-2019.

The market should grow from $1.2 billion US to $1.7 billion US in five years. North America and Europe account for 70% of global sales. Global key vendors are Transitions Optical/Essilor, Carl Zeiss, Corning, and Rodenstock. In Canada, Transitions, Carl Zeiss, Hoya, and Rodenstock share the market.

Sales of photochromic lenses are highly co-related with economic cycles. Paying for the photochromic option is still perceived as a discretionary expenditure, that customers are less interested in during uncertain economic times.

Availability of counterfeit products coupled with the cost for retailers in regions where the product is less available are hindering market growth. Rapid advances in technology and growing awareness of UV exposure are boosting growth.

The report is available at: http://www.researchandmarkets.com/research/xt5z9g/global

January 23, 2015April 24, 2018

Hema-Quebec Saves the Sight of a Child

Eye drops developed by Hema-Quebec have prevented blindness in a young child with a severe ligneous conjunctivitis.

The Quebec boy suffered from a blood plasminogen deficiency (a protein deficiency), which led to conjunctivitis. Dr. Isabelle Laliberté, pediatric ophthalmologist at the Hospital of the University of Laval, had tried everything to treat it, including fresh plasma transfusions and surgeries.

She had learned that it is possible to manufacture plasminogen concentrated eye drops, but they are not readily available on the market, due to the rarity of the disease. She contacted Louis Thibault’s team at Hema Quebec, who took on the special task and succeeded in making them. The three-year-old boy can now carry out normal day-to-day activities.

January 22, 2015April 24, 2018

Dr. Matthias Metz at the helm of Carl Zeiss Vision

As of July 1, 2015, Dr. Matthias Metz will step into the new position created on the executive board of directors at Carl Zeiss AG and will become President and CEO of Carl Zeiss Vision International.

The new executive board member will be responsible for Vision Care and Consumer Optics business groups. This underscores Carl Zeiss AG’s goal to adopt a portfolio approach, using market segmentation.

Dr. Metz has up to now held the position of chief sales and marketing officer at Fackelmann, a supplier of household, kitchen and bathroom goods. Carl Zeiss executives believe this experience is valuable for their objective to strengthen their consumer-oriented product sales.

For further information: http://www.zeiss.com/corporate/en_de/media-forum/press-releases.html?id=C65C0D445DE2AE9FC1257DCC003B6330